论文部分内容阅读
目的:探讨血清对肿瘤细胞凝集的影响,阐明血清中肿瘤细胞凝集因子的生化特性及其在瘤栓形成过程中的作用机制.方法:采用体外细胞凝集实验,通过测定未凝集细胞计算凝集率.结果:正常人、良性瘤患者及恶性实体瘤患者的血清均不同程度诱导高转移潜能人鼻咽癌细胞(CNE-2L2)凝集,细胞凝集率分别为28.2%±8.3%、33.7%±9.1%和68.7%±10.8%.但是层粘连蛋白糖肽处理L2细胞则极大地降低血清凝集活性,而且蛋白酶及高碘酸等处理血清也导致血清凝集活性的极大降低或丧失.然而正常人及良性瘤患者血清对热稳定,恶性瘤患者血清则比较敏感.结论:血清中存在肿瘤细胞凝集因子,其中正常人及良性瘤患者血清中的可能是糖复合物,而恶性瘤患者血清中的则可能是糖复合物和凝集素.它们可能在瘤栓及转移形成过程中起着重要作用,其测定可能有助于恶性肿瘤的临床诊断及预后.
Objective: To investigate the effect of serum on tumor cell agglutination and to elucidate the biochemical characteristics of tumor cell agglutinating factor in serum and its mechanism of action during tumor thrombus formation. Methods: In vitro cell agglutination assay was used to determine agglutination rate by measuring unagglutinated cells. RESULTS: Normal, benign, and malignant solid tumors all had different degrees of induction of agglutination of high metastatic potential human nasopharyngeal carcinoma cells (CNE-2L2). The cell agglutination rates were 28.2% ± 8.3% and 33.7% ± 9.1%, respectively. And 68.7%±10.8%. However, L2 cells treated with laminin glycopeptides greatly reduce serum agglutination activity, and serums such as proteases and periodic acid also cause significant reduction or loss of serum agglutination activity. However, normal and benign Serum from patients with tumors is hyperthermia, and serum from patients with malignant tumors is more sensitive. Conclusion: Tumor cell agglutination factors are present in serum. Normal and benign tumors may have glycoconjugates in their serum, whereas patients with malignant tumors may have serum It is a sugar complex and a lectin. They may play an important role in the formation of tumor thrombi and metastasis. Its determination may contribute to the clinical diagnosis and prognosis of malignant tumors.